Nar-cis-sism [nahr-suh-siz-em], noun. Inordinate fascination with oneself, excessive self-love, vanity Psychoanalysis. Gratification derived from admiration of one’s own physical or mental attributes Those regular viewer-readers of CLSDF, not those who subscribe via email or RSS (many thanks to all of the subscribers!) may have observed a new and prominently placed banner titled Big Pharma 411 [...]

• 233http://clsdf.com/2007/10/narcissism-big-pharma-411/Narcissism%3A+Big+Pharma+411%21%3F2007-10-11+20%3A42%3A00admin

No doubt about it Colorado is, to borrow poorly from Billy Joel, an RNA State of Mind. What with the Nobel Prize winning work of Tom Cech for the discovery of catalytic properties of RNA, to the work being done at Sirna now Merck (NYSE: MRK) where RNAi technology is being used to develop a [...]

• 232http://clsdf.com/2007/10/source-mdx-rna-state-of-mind/Source+MDx%3A+RNA+State+of+Mind2007-10-10+17%3A23%3A00admin

DISCLAIMER: This analysis in no way should be considered investment advice! In an effort to keep the modeling skills a bit more than dull combined with a deep-rooted curiosity about the development or lack-there-of by big pharma of new anti-infectives I remain fascinated with the progression of Replidyne’s (NASDAQ: RDYN) portfolio, particularly the antibiotic Faropenem [...]

• 231http://clsdf.com/2007/10/replidyne-is-there-value-in-antibiotics/Replidyne%3A+Is+There+Value+in+Antibiotics%3F2007-10-09+22%3A31%3A00admin

Bolder BioTechnology, uses advanced protein engineering technologies to create proprietary, long-acting human protein pharmaceuticals for the treatment of hematopoietic and endocrine disorders, cancer and infectious diseases. Now talk about achieving milestones…Bolder BioTechnology has been on a roll! Most recently BB was awarded a $685,984 Phase II SBIR grant from the National Institute of Arthritis and [...]

• 230http://clsdf.com/2007/10/bolder-biotechnology-on-a-roll/Bolder+BioTechnology+on+a+Roll2007-10-08+15%3A36%3A00admin

A must-attend CBSA BioBreakfast coming up on 24 October 7:30am to be held at the Denver Museum of Nature & Science. The distinguished panel of Dan Mitchell of Sequel Ventures, Karen Cassidy of Partisan Management Group and Andrew Schwab of 5AM Ventures will be reflecting back upon investment trends of 2007 and will provide insight [...]

• 229http://clsdf.com/2007/10/cbsa-biobreakfast-trends-in-vc-investing/CBSA+BioBreakfast%3A+Trends+in+VC+Investing2007-10-08+14%3A42%3A00admin

Accera’s Ketasyn™ performed favorably in its Phase II age-associated memory impairment study. A low incidence of adverse events along with statistical significance was achieved for Ketasyn™ as it helped to suppress a loss in memory associated with aging. The Accera pipeline includes therapeutic treatments for Parkinson’s, Alzheimer’s and other age-related memory loss disorders. The products [...]

• 228http://clsdf.com/2007/10/accera-accelerating-through-phase-ii-study/Accera+Accelerating+Through+Phase+II+Study2007-10-05+03%3A38%3A00admin

A bit of a departure from regular CLSDF posts here however, I think this is to cool not to highlight. My friend Kevin McGarvey, MD, MBA who is not only an ER physician as well as facilitating business development for ValveXchange, Inc. (a FBBp portfolio company), has also co-founded Wilderness MedVentures (WMV). How does he [...]

• 227http://clsdf.com/2007/10/wilderness-medventures-co-to-patagonia/Wilderness+MedVentures%3A+CO+to+Patagonia2007-10-02+16%3A34%3A00admin

After five years of careful planning, generous donations and hard work, the new Children’s Hospital has officially opened its doors! The old hospital on East 19th Avenue is now closed, and all inpatients have been safely moved to the new location at the Fitzsimons Life Science District where adjacent to Children’s is the future home [...]

• 226http://clsdf.com/2007/10/children%e2%80%99s-hospital-now-open-fitz/Children%E2%80%99s+Hospital+Now+Open+%40+Fitz%212007-10-01+23%3A46%3A00admin

Thanks to Larry Nelson and W3W3 for producing this fantastic interview with Rick Silva, acting Director of Fitzsimons BioBusiness Partners, Inc. (FBBp). Interview excerpt: Dr. Silva says, “It takes broad and incredibly specialized skills to build a biomedical product. Ours is the most regulated industry on Earth. Our products are among the most complex to [...]

• 225http://clsdf.com/2007/10/co-bio-ecosystem-breaking-new-ground/CO+Bio+Ecosystem+Breaking+New+Ground%212007-10-01+15%3A55%3A00admin